Table 1 Characteristics of participants
Characteristic | Â |
|---|---|
Age (year) | 32.5 (30.5–39.3) |
Sex, number (%) | Â |
 Male | 14(100) |
 Female | 0 (0) |
Ethnic group, number (%) | Â |
 Asian | 14 (100) |
 Other | 0 (0) |
 Body mass index (kg/m2) | 23.1 (20.2–26.4) |
 Time from CM to ART initiation, days | 25.5 (18.5–36.5) |
 Time from ART initiation to LEN, days | 558.0 (314.0–882.3) |
 Time from anti antifungal to LEN, days | 581.0 (340.5–906.5) |
ART regimen, number (%) | Â |
 2NRTI + 1NNRTI | 2 (14.3) |
 2NRTI + 1PI | 1 (7.1) |
 2NRTI + 1 INSTI | 11 (78.6) |
 CD4 + T-lymphocytes count/µL | 151.5 (117.0–342.3) |
HIV-RNA, number (%) | Â |
 < 50 copies/ml | 11 (78.6) |
 50–200 copies/ml | 0 |
 > 200 copies/ml | 3 (22.4) |
CD4+ T-lymphocyte count (screen), number (%) | Â |
 < 200 cells/ul | 9 (64.3) |
 200–500 cells/ul | 5 (35.7) |
 > 500 cells/ul | 0 (0) |
Clinical presentation, number (%) | Â |
 Fever | 4 (28.6) |
 Headache | 7 (50) |
 Altered mentation | 4 (28.6) |
 Seizures | 2 (14.3) |